Skip to main content
Caplight Logo









Accro Bioscience

Accro Bioscience

Private
SuzhouHealthcare & Life Scienceshttps://accropeutics.com/

Last Round

Series C

May 18, 2026

Total Funding Raised

$50M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Accro Bioscience is a biotechnology company that pioneers the discovery, development, and commercialization of novel therapeutics for inflammatory and autoimmune diseases by targeting molecular mechanisms of regulatory cell death.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Revenue Share, Services & Consulting

AI Layer

Non-AI

Keywords

oral therapeuticssmall molecule drugsregulated cell deathautoimmune disease therapeuticsRIPK2 inhibitorclinical-stage biotechUlcerative Colitisinflammatory disease therapeuticsdrug discoverybiotech licensingTYK2/JAK1 inhibitorplaque psoriasisIBD treatmentRIPK1 inhibitorGraft-versus-Host Disease

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Accro Bioscience Comparables

Compare Accro Bioscience with similar companies based on industry and business-model similarity.

Accro Bioscience comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Chengdu Zeling Biomedical Technology Co. Ltd.
86%
杭州高光制药股份有限公司
86%
Odyssey Therapeutics
84%

Accro Bioscience Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series CMay 18, 2026

Accro Bioscience Investors

Notable investors and investment history

Accro Bioscience investors
InvestorRounds
TCG CrossoverSeries C
Centurium CapitalSeries C
Oriza HoldingsSeries C
Shenzhen Capital GroupSeries C
OrbiMedSeries C
Cenova CapitalSeries C
Lilly Asia VenturesSeries C

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 21, 2026

    Monthly visitors increased 78% MoM.

  • May 18, 2026

    $50M round led by OrbiMed.

Accro Bioscience Filings

Explore SEC and related filing metadata, where available.

Accro Bioscience filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Accro Bioscience's valuation, stock price, and market status.

Is Accro Bioscience Inc. a public or private company?

Accro Bioscience Inc. is a private company.

What is the current stock price of Accro Bioscience Inc.?

Accro Bioscience Inc. is a private company with no public stock price. No recent secondary market data is available.

How much is Accro Bioscience Inc. worth (valuation)?

Valuation information for Accro Bioscience Inc. is not publicly available.

Can I buy Accro Bioscience Inc. stock?

Accro Bioscience Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Accro Bioscience Inc.'s last funding round?

Accro Bioscience Inc.'s most recent funding round was Series C on May 18, 2026.

Who are the main investors in Accro Bioscience Inc.?

Key investors in Accro Bioscience Inc. include OrbiMed.

Will Accro Bioscience Inc. IPO soon?

No public IPO plans have been announced for Accro Bioscience Inc..

How can I track Accro Bioscience Inc. secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Accro Bioscience Inc.'s secondary market activity and sign up for updates.

Firmographic Details

HeadquartersSuzhou
Employee Range3
Year Founded2017
Last FundingMay 18, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?